Enzymotec Krill Launches in Indian Product

April 11, 2011

2 Min Read
Enzymotec Krill Launches in Indian Product

MIGDAL HAEMEQ, IsraelEnzymotec Ltd. signed a long-term contract with Lupin Limited, Mumbai, India, to include its krill oil in a product, The Krill Oil +, which will be launched later this year in the Indian market.

"Both companies strongly believe the Indian market holds a huge potential for Krill oil and the issues of quality, freshness and efficacy would play a front role in its establishment," said Mr. Boaz Noy, Enzymotec's senior vice president.

"The deal is part of Enzymotecs strategic penetration to the Asian markets. This launch will be followed by many more," said Gil Kristovsky, Enzymotec's business unit manager

Enzymotec is a biotech company and a global developer, producer and supplier of lipid-based products and solutions. Enzymotec develops, manufactures and markets innovative bioactive ingredients and finished products based on proprietary technologies. Enzymotec's products support general health, from cardiovascular to cognitive functions, in large therapeutic markets.

Lupin Limited is a pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world. The Company has presence in cardiovasculars (prils and statins), diabetology, asthma, pediatrics, CNS, GI, anti-infectives, NSAIDs, anti-TB and cephalosporins. The Companys R&D endeavors have resulted in significant progress in its NCE program. The companys foray into advanced drug delivery systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Lupin is the 5th largest and the fastest growing Top 5 company in the United States (by prescriptions), the only Asian company to achieve that distinction. The company is also the fastest growing, top 5 pharmaceutical players in India (ORG IMS) and the fastest growing, top 10 Generic players in Japan and South Africa (IMS).For the financial year ended March 2010, Lupin's Consolidated Sales and Profit after Tax were RS47,678 million and RS6,816 million respectively.

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like